Author

I. Berest

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:chromatin & epigenetic regulation· 2 Organism:human· 2 Organism:mouse· 2 Assay:ChIP-seq· 1 Approach:deep learning· 1

Frequent Co-Authors

J. B. Zaugg· 2 shared A. Cvejic· 1 shared A. Lechner· 1 shared A. M. Ranzoni· 1 shared A. Tangherloni· 1 shared B. Myers· 1 shared C. Kolb· 1 shared C. Müller-Tidow· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. B. Zaugg

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Tuft cell IL-17RB restrains IL-25 bioavailability and reveals context-dependent ILC2 hypoproliferation

X. Feng, T. Andersson, J. Gschwend, P. Flüchter, I. Berest, J. L. Muff, D. Carchidi, A. Lechner, J. C. de Tenorio, N. Brander, U. Boehm, C. S. Klose, D. Artis, T. Leinders-Zufall, F. Zufall, C. Schneider

The paper shows tuft cell IL-17RB limits IL-25 bioavailability, preventing excessive ILC2 activation and causing hypoproliferation under certain conditions.

bioRxiv · Mar 4, 2024Immunology

Combinatorial drug-microenvironment interaction mapping reveals cell-extrinsic drug resistance mechanisms and clinically relevant patient subgroups in CLL

P.-M. Bruch, H. A. R. Giles, C. Kolb, S. A. Herbst, T. Becirovic, T. Roider, J. Lu, S. Scheinost, L. Wagner, J. Huellein, I. Berest, M. Kriegsmann, K. Kriegsmann, C. Zgorzelski, P. Dreger, , S. Dietrich

This paper maps drug-microenvironment interactions in CLL to identify resistance mechanisms and patient subgroups, revealing how microenvironmental stimuli and genetic alterations influence drug response.

bioRxiv · Jul 23, 2021 · PreprintCancer Biology

Integrative Single-cell RNA-Seq and ATAC-Seq Analysis of Human Developmental Haematopoiesis

A. M. Ranzoni, A. Tangherloni, I. Berest, S. G. Riva, B. Myers, P. M. Strzelecka, J. Xu, E. Panada, I. Mohorianu, J. B. Zaugg, A. Cvejic

The paper uses scRNA-Seq and scATAC-Seq to analyze human blood cells, identifying proliferative progenitors and epigenetic priming in haematopoiesis.

bioRxiv · May 6, 2020 · PreprintCell Biology

TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells

K. Rasmussen, I. Berest, S. Kessler, K. Nishimura, L. Simon-Carrasco, G. S. Vassilou, M. T. Pedersen, J. Christensen, J. Zaugg, K. Helin

This study shows TET2 binding to enhancers in hematopoietic cells supports transcription factor recruitment, and its loss disrupts chromatin binding of CDX4, linking epigenetic regulation to disease.

bioRxiv · May 31, 2018Cancer Biology